Tabimorelin

Tabimorelin is a synthetic peptide that functions as a growth hormone secretagogue, meaning it stimulates the body to release its own growth hormone (GH). It was developed and investigated for its potential therapeutic applications, particularly in conditions characterized by GH deficiency or where increased GH levels could be beneficial. Unlike exogenous growth hormone administration, tabimorelin aims to enhance physiological GH secretion by acting on the pituitary gland. The peptide interacts with ghrelin receptors, also known as growth hormone secretagogue receptors (GHSRs). These receptors are found in various tissues, including the hypothalamus and pituitary, where they play a crucial role in regulating appetite, energy balance, and growth hormone release. By activating these receptors, tabimorelin mimics the action of ghrelin, a naturally occurring hormone. Early research on tabimorelin focused on its ability to increase GH and insulin-like growth factor 1 (IGF-1) levels, which are important for tissue growth, metabolism, and overall cellular function. Its development was part of a broader effort to find orally active compounds that could modulate the growth hormone axis. (Source: PubChem, DrugBank)